Clinical trials: Respiratory Disorder
Pneumonia, Severe Acute Respiratory Syndrome
Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19
This phase III trial compares low dose whole lung radiation therapy to best supportive care plus physicians choice in treating patients with COVID-19 infection.
- Conditions
- Pneumonia, Severe Acute Respiratory Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
- Trial name
- RESCUE1-19 (NCT04433949)
- Testing
- Best Practice, Low Dose Radiation Therapy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Emory University
Vaccine Response Impaired, Vaccine Adverse Reaction
Vaccine Observation to Include All Communities for Equitable Science
VOICES is a longitudinal, prospective, observational study that will enroll up to 10,000 subjects of diverse racial backgrounds being administered an emergency use authorized COVID-19 vaccine, for collection and analysis of stool…
- Trial name
- VOICES (NCT04770649)
- Testing
- COVID-19 vaccine
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Persephone Biosciences
Non Small Cell Lung Cancer Stage III
Accelerated Radio-Immunotherapy for Lung Cancer
Radiotherapy (RT), at a total dose of 60-66 Gy over 6 weeks, combined with platinum-based chemotherapy, is the standard of care for stage III Non-Small Cell Lung Cancers (NSCLC) patients with unresectable or inoperable disease.
- Trial name
- AIRING (NCT04577638)
- Testing
- Nivolumab and Intensity Modulated Radiotherapy (IMRT)
- Where
- 5 sites in France
- Volunteers
- 8 people
- Sponsor
- Center Eugene Marquis
Lung Diseases, Asthma
Better Asthma Outcomes: Lowering Tobacco Smoke Exposure
To improve disease outcomes through reduction in secondhand tobacco smoke exposure of children with asthma
- Trial name
- NCT00217958
- Testing
- SHS reduction intervention based on social cognitive learning theory
- Sponsor
- Palo Alto Medical Foundation
Covid-19
Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression
This is a randomized, double-blind, placebo-controlled, multicenter, Phase 3 study to evaluate if high-dose Octagam 10% therapy can stabilize or improve clinical status in patients with severe Coronavirus disease
- Trial name
- NCT04400058
- Testing
- Octagam 10%, Saline Solution
- Where
- 22 sites in United States, Russia and 1 more
- Volunteers
- 207 people
- Sponsor
- Octapharma
COVID-19
Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine
This is a double blind, placebo controlled study in approximately 2,000 health care workers at risk for being exposed to COVID-19.
- Trial name
- HERO-HCQ (NCT04334148)
- Testing
- Hydroxychloroquine
- Where
- 34 sites in United States
- Volunteers
- 1,360 people, healthy volunteers welcome
- Sponsor
- Adrian Hernandez
Breast Cancer
Respiratory Muscle Strength Training to Prevent Respiratory Muscle Weakness in Adults Newly Diagnosed With Breast Cancer
The goal of this clinical trial is to learn if respiratory muscle strength training can prevent respiratory muscle weakness in adults who are newly diagnosed with breast cancer and are planning to have surgery.
- Trial name
- NCT07229378
- Testing
- Respiratory muscle strength training, Guided Imagery Exercises
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Florida
Laryngeal Cancer, Hypopharynx Cancer
Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer
This study is a prospective, single-arm, single-center, phase II study. The goal of this clinical trial is to explore the therapeutic value of the treatment model of "tislelizumab combined with chemotherapy followed by…
- Conditions
- Laryngeal Cancer, Hypopharynx Cancer, Laryngeal Neoplasms
- Trial name
- NCT06554028
- Testing
- chemotherapy TP regimen combined with Tislelizumab
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Henan Cancer Hospital
Pulmonary Arterial Hypertension
Safety, Tolerability, & Pharmacokinetics Study of Single & Multiple Inhaled Doses of Imatinib Inhalation Solution
This is a randomised, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and PK of single and multiple inhaled doses of imatinib inhalation solution (AER-901) in healthy adult…
- Trial name
- NCT04903730
- Testing
- AER-901 Solution for Nebulization
- Where
- Australia
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Aerami Therapeutics
Hemoptysis, Haemoptysis
Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis
The study consist of a retrospective analysis of the etiologies, investigations and outcomes of patients presenting between 2005 to 2010 with hemoptysis in a North-American Tertiary center.
- Conditions
- Hemoptysis, Haemoptysis, Lung Disease, Pneumonia
- Trial name
- NCT02913365
- Where
- Canada
- Volunteers
- 1,000 people
- Sponsor
- Université de Sherbrooke
COPD
Effects of Lysozyme on Acute Exacerbation of Chronic Obstructive Pulmonary Disease : A Randomised Placebo-Controlled Study
The aim of this study is to assess the effectiveness in preventing exacerbation of 52 weeks lysozyme administration in patients with COPD.
- Trial name
- NCT01645800
- Testing
- Lysozyme hydrochloride
- Where
- 25 sites in Japan
- Volunteers
- 408 people
- Sponsor
- Eisai Co., Ltd.
Sars-CoV-2 Infection
Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection
This is a phase 2b prospective, randomized, single-blind, controlled trial of a single subcutaneous injection of peginterferon lambda-1a versus placebo for prevention of SARS-CoV-2 infection in non-hospitalized participants at…
- Trial name
- PROTECT (NCT04344600)
- Testing
- Peginterferon lambda alfa-1a subcutaneous injection, Saline
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Johns Hopkins University
Hantavirus Pulmonary Infection, Immunisation
Andes Virus DNA Vaccine for the Prevention of Hantavirus Pulmonary Syndrome Using the PharmaJet Stratis(R) Needle-Free Injection Delivery Device
This is a Phase 1, randomized, placebo controlled, double-blind, dose escalation trial of 48 males and non-pregnant females, 18-49 years old, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03682107
- Testing
- Andes virus DNA vaccine
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Bronchiolitis Obliterans Syndrome
Imaging and Understanding BOS in Lung Transplantation
This study is a prospective, non-randomized, longitudinal, observational study that will recruit about 5 lung transplant patients per year for 3 years.
- Trial name
- NCT02316392
- Testing
- Hyperpolarized Helium-3 MRI
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Non-Small Cell Lung Cancer, Myelosuppression
Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC
This study is a prospective, single arm phase II study aimed at patients with locally advanced or metastatic non-small cell lung cancer undergoing second-line or beyond treatment.
- Trial name
- PROTECT-1 (NCT06929936)
- Testing
- Trilaciclib combined with Docetaxel
- Where
- China
- Volunteers
- 33 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Covid19, Endothelial Dysfunction
Managing Endothelial Dysfunction in Critically Ill COVID-19 Patients at LAUMCRH
COVID-19 Infection has been found to cause endothelial dysfunction and most of the adverse events stem to this mechanism. So we seek to target endothelial dysfunction in critically Ill patients with covid by giving them an…
- Trial name
- NCT04813471
- Testing
- Endothelial Protocol
- Where
- Lebanon
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Lebanese American University Medical Center
Ventilator-Associated Pneumonia (VAP)
Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (CIVAP): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial
Previous studies have identified Acinetobacter baumannii (AB), Pseudomonas aeruginosa (PA), and Klebsiella pneumoniae (KP) as the predominant pathogens responsible for ventilator-associated pneumonia (VAP).
- Trial name
- CIVAP (NCT06834971)
- Testing
- Colistimethate sodium (CMS)
- Where
- China
- Volunteers
- 508 people
- Sponsor
- Qilu Hospital of Shandong University
Respiratory Tract Infections, Infections
Non-specific Effects of a Modified Measles Vaccination Schedule to Prevent Allergy and Unrelated Infection in Children
The goal of this clinical trial is to evaluate the off-target/non-specific effects of the measles-mumps-rubella (MMR) vaccine in children.
- Conditions
- Respiratory Tract Infections, Infections, Allergy, Eczema
- Trial name
- NEMAU (NCT05758532)
- Testing
- Measles-Mumps-Rubella vaccine (MMR)
- Where
- Switzerland
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Laure Pittet, MD-PhD
Community Acquired Pneumonia (CAP)
ItAlian ReGistry Of pNeumoniA in immUnocompromised paTients (ARGONAUT)
This multicentric, prospective study aims at: evaluating the prevalence, etiology, characteristics, and 1one-year outcomes of immunocompromised patients hospitalized for Community-Acquired Pneumonia (CAP); conducting biochemical…
- Trial name
- ARGONAUT (NCT06755814)
- Where
- Italy
- Volunteers
- 1,298 people
- Sponsor
- Societa Italiana di Pneumologia
Altitude Hypoxia
Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders Older Than 40 Years at Altitude.
Randomized, placebo controlled trial evaluating efficacy of acetazolamide on right heart function at rest in lowlanders older than 40 years travelling from 760 m to 3'100 m.
- Trial name
- NCT03540914
- Testing
- ACETAZOLAMIDE oral capsule
- Where
- Kyrgyzstan
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of Zurich
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.